Condition (MeSH)
Thrombocytosis
ClinicalTrials.gov lists 252 trials for Thrombocytosis or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 13.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
1 more section with rows
32 of the 252 trials are tagged with Thrombocytosis itself; the rest are tagged with a narrower condition beneath it.
When did Thrombocytosis trials start? (33)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
- Other (Unknown)
Top of scale: 14
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 8 |
| 2025 | 7 |
| 2024 | 11 |
| 2023 | 8 |
| 2022 | 7 |
| 2021 | 8 |
| 2020 | 12 |
| 2019 | 6 |
| 2018 | 7 |
| 2017 | 8 |
Showing 10 of 33 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 10 trials starting in 2026 and about 10 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 36 months from start to primary completion across 26 trials still running at the 2026-10-09 snapshot; registered median of 41 months across 173 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Thrombocytosis trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 50 |
| Phase 1/2 | 25 |
| Phase 2 | 69 |
| Phase 2/3 | 2 |
| Phase 3 | 31 |
| Phase 4 | 3 |
| Not applicable | 23 |
| Observational | 48 |
| Unknown | 1 |
How many Thrombocytosis trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 6 |
| Recruiting | 35 |
| Active, not recruiting | 21 |
| Completed | 141 |
| Terminated | 28 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Thrombocytosis trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 13 |
| Incyte Corporation | 10 |
| Shire | 8 |
| AOP Orphan Pharmaceuticals AG | 4 |
| European Organisation for Research and Treatment of Cancer - EORTC | 4 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Thrombocytosis? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Cytoxan | 23 |
| Busulfan | 18 |
| Anagrelide | 10 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| SQ Fludarabine | 24 |
| Peripheral blood stem cell transplantation | 22 |
| Ruxolitinib IR | 19 |
| IR Tacrolimus | 15 |
| Cyclosporine 0.05% | 13 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Thrombocytosis trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pneumonia | 145 | 17 |
| 1 yr TRM | 93 | 1 |
| Anaemia | 75 | 11 |
| Pyrexia | 57 | 10 |
| Anemia | 52 | 7 |
Showing 5 of 10 adverse events.
Which publications cover Thrombocytosis? (33)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Immune-mediated thrombocytopenia and IL-6-mediated thrombocytosis observed in idiopathic multicentric Castleman disease. | British journal of haematology | 2024 | Yes |
| Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. | NEJM evidence | 2023 | Yes |
| Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. | Leukemia | 2022 | Yes |
| Sequential mutational evaluation of CALR -mutated myeloproliferative neoplasms with thrombocytosis reveals an association between CALR allele burden evolution and disease progression. | British journal of haematology | 2020 | Yes |
| Association of thrombocytosis with COPD morbidity: the SPIROMICS and COPDGene cohorts. | Respiratory research | 2018 | Yes |
Showing 5 of 33 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.